Braveheart
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Letterman Dr Ste A Bldg A, San Francis...Phone Number
(415) 707-6312Website
braveheart.bioRevenue
-Industry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
2
1
About Braveheart
Braveheart Bio is a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related conditions. The company is backed by experienced life science investors including Andreessen Horowitz (a16z Bio + Health), Forbion, OrbiMed, Enavate Sciences (a platform of Patient Square Capital), and Frazier Life Sciences.Explore more
Braveheart Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Braveheart your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Braveheart, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Braveheart launches new products
Earning: See what the market has to say on Braveheart recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Braveheart
Click to see if Braveheart had a recent Job posting/layoffs
Check out if Braveheart is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Braveheart has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Braveheart has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Braveheart is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Braveheart is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Braveheart.
Braveheart financials insights
Gather financial insights about Braveheart, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Series A
$185M
Braveheart Tech Stack
A closer look at the technologies used by Braveheart
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Open Position
Open Position
Hiring Plans
Hiring Plans
Braveheart News & Media
Braveheart Bio CFO Acquires 27,777 Shares for $500,000. Is This a Signal BRVE IPO Is a Success?
Option exercise expands executive's long-term equity stake to 612,251 shares, now valued at $18.37 million based on August 7 market close.Braveheart Bio Chairman Chris Viehbacher Buys $1.5M Shares at IPO. What Does This Mean for Investors?
Insider exercise expanded his direct stake by 16% to 609,519 shares, bringing total beneficial ownership to ~760,000 shares valued at $22.8 million.Braveheart Bio CEO Travis Murdoch Buys 83,333 Shares for $1.5 Million. Is This a Buy Signal for Investors?
Murdoch exercised options at $18 per share, increasing his total beneficial ownership to ~8 million shares valued at $161 million, representing a 13% stake.Goodwin Advises Braveheart Bio on $439.9 Million Closing of Upsized Initial Public Offering
Goodwin advised Braveheart Bio on its $439.9 million upsized IPO, supporting the clinical-stage biopharmaceutical company as it began trading on Nasdaq.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Braveheart
Sign Up For FreeTo access detailed company insights
Braveheart Bio is a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related conditions. The company is backed by experienced life science investors including Andreessen Horowitz (a16z Bio + Health), Forbion, OrbiMed, Enavate Sciences (a platform of Patient Square Capital), and Frazier Life... Read More
